BERLIN (Reuters) – The German government expects vaccinations with the Novavax COVID-19 vaccine Nuvaxovid to begin across the country over the course of this week, a Health Ministry spokesperson said on Monday.
“We assume that over the coming week … vaccinations can begin in the federal states,” the spokesperson told a regular government news conference.
Novavax’s recombinant protein vaccine uses a more established technology than mRNA, the novel method behind the two most commonly used COVID-19 vaccines in Germany – from Pfizer/BioNTech and Moderna.
Public health leaders have voiced hopes Novavax’s product could convince as-yet unvaccinated people who are sceptical about the novel mRNA technology to get a shot.
(Writing by Paul Carrel and Kirsti Knolle; Editing by Maria Sheahan)
